摘要
目的观察伊立替康(开普拓)联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法经病理学或细胞学确诊的初治晚期NSCLC患者15例,男性10例,女性5例,中位年龄47岁(32～58岁),KPS评分>70。接受顺铂80mg/m2联合伊立替康60mg/m2,第l、8、15天静脉滴注,每4周重复。至少2周期后评价疗效。结果全组PR4例,SD9例,PD2例,总有效率26.7%。中位生存时间11个月,1年生存为率46.7%(7/15)。主要不良反应为延迟性腹泻和粒细胞减少。结论伊立替康联合顺铂治疗晚期NSCLC疗效确切,不良反应发生率低,耐受性较好。
Objective To evaluate the efficacy and adverse effects of irinotecan combined with cisplatin in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods Fifteen patients（10 males and 5 females） aged from 32 to 58 years（median age of 47 years） with KPS〉70 and the diagnosis of advanced NSCLC by pathology or cytology were treated with cisplatin 80 mg/m^2 plus irinotecan 60 mg/m^2 by intravenous infusion on 1,8,15 days,and the treatment was repeated every 4 weeks.After treatment for at least 2 cycles,the therapeutic effects and adverse drug reactions were evaluated.Results Of all the cases,PR was achieved in 4（26.7%）,SD in 9（60%）,and PD in 2（13.3%）,with an overall response rate of 26.7%.The median survival time was 11 months and 1-year survival rate was 46.7%（7/15）.The main toxicities were delayed diarrhea and granulocytopenia.Conclusion Irinotecan plus cisplatin is an effective and tolerable treatment for advanced NSCLC with low incidence of adverse effects.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2010年第2期349-350,共2页
Journal of Southern Medical University
